This randomized controlled study demonstrates that patients achieved a higher percentage of target hemoglobin levels. Patients receiving anemia management assistance via the software tools saw a 25% reduction in erythropoiesis-stimulating agent (ESA) usage. The software’s physiology-based model and predictive controller were associated with improved hemoglobin fluctuations and variability, offering a higher likelihood of more stable hemoglobin levels compared to standard care protocols.
Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, today announced innovative results from a multicenter, randomized controlled trial in the United States that highlights the potential benefits of personalized anemia therapy for patients undergoing hemodialysis. The study, „Effects of Individualized Anemia Therapy on Hemoglobin Stability,“ published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrates that the use the anemia therapy assistance software, attained improved hemoglobin stability and reduced the use of erythropoiesis-stimulating agents (ESAs) among hemodialysis patients participating in the study.
https://journals.lww.com/cjasn/fulltext/2024/09000/effects_of_individualized_anemia_therapy_on.10.aspx
